Proto-Oncogene Proteins p21(ras) Concept

subject area of

• A Phase II Study of Neoadjuvant Opnurasib KRAS G12C Inhibitor in Patients With Surgically Resectable Non-Small Cell Lung Cancer (CCTG IND.242A): A Substudy of the IND.242 Platform Master Protocol.  Journal Articles
• A primary DICER1-sarcoma with KRAS and TP53 mutations in a child with suspected ECCL  Journal Articles
• A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors  Journal Articles
• Activated KRAS, polyamines, iASPP and TME: a multiple liaison in pancreatic cancer  Journal Articles
• Adjuvant Chemotherapy With or Without Biologics Including Antiangiogenics and Monoclonal Antibodies Targeting EGFR and EpCAM in Colorectal Cancer: A Systematic Review and Meta-analysis  Journal Articles
• Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC  Journal Articles
• Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial  Journal Articles
• Humanized mouse models of KRAS-mutated colorectal and pancreatic cancers with HLA-class-I match for pre-clinical evaluation of cancer immunotherapies.  Journal Articles
• Insulin Activates a p21-activated Kinase in Muscle Cells via Phosphatidylinositol 3-Kinase  Journal Articles
• Insulin, Insulin-like Growth Factor-I, and Platelet-Derived Growth Factor Activate Extracellular Signal-Regulated Kinase by Distinct Pathways in Muscle Cells  Journal Articles
• Multiple Signaling Pathways Control the Activation of the CEF-4/9E3 Cytokine Gene by pp60v-  Journal Articles
• Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer  Journal Articles
• Permissiveness of Human Cancer Cells to Oncolytic Bovine Herpesvirus 1 Is Mediated in Part by KRAS Activity  Journal Articles
• Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors  Journal Articles
• Presentation and outcomes of KRASG12C mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence  Journal Articles
• Primary Explants of Human Uroepithelium Show an Unusual Response to Low-Dose Irradiation with Cobalt-60 Gamma Rays  Journal Articles
• Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial  Journal Articles
• Reversion of middle T antigen-transformed Rat-2 cells by Krev-1: implications for the role of p21c-ras in polyomavirus-mediated transformation.  Journal Articles
• Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Journal Articles
• Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219  Journal Articles
• The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma  Journal Articles
• Treatment patterns and outcomes in KRAS‐positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study  Journal Articles
• β-Subunit of the voltage-gated Ca ²⁺ channel Cav1.2 drives signaling to the nucleus via H-Ras  Journal Articles